IP Verse

Combination Anti Cancer Therapy With An Iap Antagonist And An Anti Pd-1 Molecule

Patent No. EP3728313 (titled "Combination Anti Cancer Therapy With An Iap Antagonist And An Anti Pd-1 Molecule") was filed by Debiopharm on Dec 21, 2018. The application was issued on Oct 25, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KRAUS & LEDERER PARTGMBBApr 30, 2024ELKINGTON AND FIFE
KRAUS & LEDERER PARTGMBBApr 30, 2024KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3728313

DEBIOPHARM
Application Number
EP18829861A
Filing Date
Dec 21, 2018
Status
Granted And Under Opposition
Jun 30, 2023
Publication Date
Oct 25, 2023
External Links
Slate, Register , Google Patents